There are 203 resources available
46P - Targeting transforming growth factor beta (TGF-β) using pirfenidone: A potential repurposing therapeutic strategy in colorectal cancer
Presenter: Amir Avan
Session: Poster Display & Cocktail
Resources:
Abstract
47P - Final analysis of the randomized phase II cohort of CM24 with nivolumab and chemotherapy in pancreatic cancer and potential serum biomarkers
Presenter: Michael Schickler
Session: Poster Display & Cocktail
Resources:
Abstract
48P - Camrelizumab combined with concurrent chemoradiotherapy for locally recurrent esophageal cancer: A single-arm, open-label study
Presenter: Ruinuo Jia
Session: Poster Display & Cocktail
Resources:
Abstract
49P - Outcome of patients with early-onset cancer in phase I trials with immune checkpoint inhibitors
Presenter: Oriol Mirallas
Session: Poster Display & Cocktail
Resources:
Abstract
50P - Comparison of efficacy between lenvatinib and bevacizumab in combination of immune checkpoint inhibitor and interventional triple therapy in Chinese advanced hepatocellular carcinoma: CLEAP 2302 study
Presenter: Zhaolong Pan
Session: Poster Display & Cocktail
Resources:
Abstract
51P - A preliminary study on the application of a strong combination induction of immune checkpoint inhibitors with targeted therapy and chemotherapy in head and neck tumors
Presenter: Junjun Zhou
Session: Poster Display & Cocktail
Resources:
Abstract
52P - Clinical outcomes of relapsed or refractory classical Hodgkin lymphoma, including those unsuitable or refractory to stem cell transplant
Presenter: Mia Giles
Session: Poster Display & Cocktail
Resources:
Abstract
53P - Exploring the clinical and therapeutic implications of non-hotspot mutations in POLE
Presenter: Marta Amann Arevalo
Session: Poster Display & Cocktail
Resources:
Abstract
54P - An investigation addressing the association between socioeconomic status and immunotherapy toxicities in lung cancer patients
Presenter: Tamar Sollman
Session: Poster Display & Cocktail
Resources:
Abstract
55P - Real-world study of serplulimab plus chemotherapy as second or further-line therapy for small cell lung cancer
Presenter: Yanrong Guo
Session: Poster Display & Cocktail
Resources:
Abstract